Do people want to know if they are at risk for Alzheimer’s disease?
- Jul 10, 2012
Genetic tests exist to identify risk for the rare inherited form of early-onset Alzheimer’s disease (AD) and to predict susceptibility to the more common, late-onset form of AD, but do people want to know, and how do they react? The answers can be found in the article published in Genetic Testing and Molecular Biomarkers, a peer-reviewed journal from Mary Ann Liebert, Inc. The article is available free on the Genetic Testing and Molecular Biomarkers website.
“This article addresses a major disease of tremendous impact on increasing numbers of people and documents the large psychological component that physicians and genetic counselors must be ready to address.” says Kenneth I. Berns, MD, PhD, Editor-in-Chief of Genetic Testing and Molecular Biomarkers, and Director of the University of Florida’s Genetics Institute, College of Medicine, Gainesville, FL.
In the article “To Know or Not to Know: An Update of the Literature on the Psychological and Behavioral Impact of Genetic Testing for Alzheimer Disease Risk,” B. Rahman and a team of researchers from Australia review the latest studies on whether people at risk for early-onset familial AD want to know their genetic profile and actually undertake testing, and how they tend to respond to the results. They also evaluate the attitudes of the general population and people with a family history of late-onset AD toward testing for disease risk factors and what motivates them to undergo genetic testing.
About the Journal
Genetic Testing and Molecular Biomarkers is an authoritative peer-reviewed journal published 10 times per year in print and online that reports on all aspects of genetic testing, including molecular and biochemical based tests and varied clinical situations; ethical, legal, social, and economic aspects of genetic testing; and issues concerning effective genetic counseling. Tables of contents and a free sample issue may be viewed on the Genetic Testing and Molecular Biomarkers website.
About the Publisher
Mary Ann Liebert, Inc. is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Human Gene Therapy and OMICS. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 70 journals, books, and newsmagazines is available at Mary Ann Liebert, Inc..
Mary Ann Liebert, Inc./Genetic Engineering News
Also in this section
- Study finds that sleep apnea and Alzheimer’s are linked
- APA Leaders Defend New Diagnostic Guide
- One million Dementia Friends will help make life better for people with dementia
- Expressions of interest for funding to improve care environments for people with dementia
- Dementia Facts And Statistics: Present And Future
- Cancer drug prevents build-up of toxic brain protein
- Could eating peppers prevent Parkinson’s?
- Promising Alzheimer’s Drug Fails in Study
- No link between anesthesia, dementia in elderly, Mayo Clinic Study finds
- Mild blast injury causes molecular changes in brain akin to Alzheimer, Pitt team says
- Swedish study suggests reduced risk of dementia
- Gene May Help Identify Risk of Alzheimer’s in African Americans
Post a comment [ + Comment here + ]
There are no comments for this entry yet. [ + Comment here + ]
Comments are moderated by our editors, so there may be a delay between submission and publication of your comment. Offensive or abusive comments will not be published.